Sonic Incytes
Vancouver, CA · Founded 2017 · 47 employees on LinkedIn · 2 known investors
Sonic Incytes Medical Corp. develops Velacur ONE, an AI-guided ultrasound system that provides quantitative liver stiffness and attenuation measurements at the point of care. The technology supports non-invasive detection and monitoring of metabolic liver disease (MASLD and MASH) for clinicians and healthcare providers.
Also known as Sonic Incytes Medical Corp.
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Sonic Incytes Medical Corp. develops Velacur ONE, a point-of-care ultrasound elastography device that measures liver tissue elasticity (stiffness) and attenuation as indicators of MASLD and MASH. The company positions the measurements as comparable to invasive and non-invasive reference standards, specifically biopsy and MRE/MRI-PDFF, and states the system is clinically validated against both.
The examination follows a three-step workflow: an activation pad placed under the patient's back generates multi-frequency steady-state shear waves through the liver; the operator sweeps the probe with AI guidance to acquire 3D volumetric measurements of liver tissue; and elasticity and attenuation results are produced in real time so that results can be discussed during the same visit. The procedure is described as non-invasive and performable in-office by any trained medical professional.
Traction
Velacur ONE holds FDA 510(k) clearance and the company cites clinical research validating the device against invasive and non-invasive reference standards, plus reimbursement guidance for liver elastography CPT coding. [0]
Latest developments
In August 2025 the company announced FDA 510(k) clearance for Velacur ONE for the management of chronic liver diseases. In June 2026 it announced being named 2026 MedTech Emerging Company of the Year. Julia Pinter, previously Director of Global GI Product Marketing at PENTAX Medical, joined as Marketing Director leading downstream marketing. [0]
▸Full profile — market position, technology, go-to-market
Market position
Operates in non-invasive liver assessment, competing with transient elastography and with MRE/MRI-PDFF and biopsy as reference standards. Velacur ONE received FDA 510(k) clearance in 2025 and the company was named 2026 MedTech Emerging Company of the Year. [0]
Marketed on three claimed advantages: accuracy validated against biopsy and MRE/MRI-PDFF; AI guidance plus portable design intended to reduce operator dependence; and economics based on low capital cost, short procedure time and reimbursement described as 3-4 times higher than other non-imaging elastography. [0]
Technology
Velacur ONE combines the company's S-WAVE shear-wave approach with AI-guided imaging. A pad placed beneath the patient generates multi-frequency steady-state shear waves in the liver, and a sweeping probe motion produces 3D volumetric elasticity and attenuation measurements. Two AI features are described: Organ Guide, which helps operators locate the liver and obtain measurements even with inexperienced operators or high-BMI patients, and Wave Quality, which performs automatic wave detection to improve scan quality and enables greater measurement depth and sample volume — stated as twice the depth and 30 times the volume of transient elastography. [0]
Go-to-market
Direct commercial engagement via demo requests, product videos and downloadable materials including a product brochure and a reimbursement guide; a dedicated downstream marketing function supports awareness and adoption. [0]
Clinicians and healthcare providers performing liver assessment at the point of care, including in-office settings where trained medical professionals conduct the scan. [0]
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsJulia Pinter, formerly Director of Global GI Product Marketing at PENTAX Medical, leads downstream marketing at Sonic Incytes.
Sonic Incytes announced FDA 510(k) clearance for Velacur ONE, an AI-guided point-of-care ultrasound for the management of chronic liver diseases.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- Sonic Incytessonicincytes.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Sonic Incytes do?
- Sonic Incytes makes Velacur ONE, an AI-guided point-of-care ultrasound elastography system for chronic liver disease assessment.
- Who are Sonic Incytes's investors?
- Sonic Incytes's investors include Flucas Ventures, Wavemaker Three-Sixty Health.
- Where is Sonic Incytes headquartered?
- Sonic Incytes is headquartered in Vancouver, CA.